Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Health Catalyst provides cloud-based data analytics and decision support platforms to healthcare organizations, primarily hospitals and health systems, enabling them to improve clinical outcomes and reduce costs through data-driven insights. The company operates in a fragmented healthcare IT market competing against Epic, Cerner/Oracle, and specialized analytics vendors. With a $100M market cap, negative margins, and 68% stock decline over 12 months, the company faces significant profitability challenges despite modest 3.6% revenue growth.
Health Catalyst sells multi-year SaaS subscriptions to hospital systems for its data operating system (DOS) and analytics applications that aggregate clinical, financial, and operational data. Revenue is recognized ratably over contract terms (typically 3-5 years). The company monetizes through platform expansion (adding modules), user seat expansion within existing clients, and cross-selling specialized applications for population health, quality improvement, and cost reduction. Gross margins of 46% reflect cloud infrastructure costs and professional services delivery. Pricing power is moderate, constrained by hospital budget pressures and competitive alternatives from EHR vendors bundling analytics.
Net new annual recurring revenue (ARR) bookings and client logo additions, particularly large health system wins
Technology revenue growth rate and shift in revenue mix away from lower-margin professional services
Customer retention rates and expansion revenue from existing clients (net revenue retention metric)
Path to profitability milestones: adjusted EBITDA margin improvement and timeline to positive operating cash flow
Healthcare IT M&A activity and potential takeout speculation given depressed valuation (0.4x P/S)
EHR vendor encroachment: Epic, Oracle/Cerner, and Meditech increasingly bundle analytics capabilities, reducing standalone platform demand and pricing power
Regulatory uncertainty around healthcare data interoperability and privacy (HIPAA, 21st Century Cures Act) could increase compliance costs or disrupt business model
Shift toward value-based care adoption slower than anticipated, reducing urgency for advanced analytics investments by fee-for-service-dominant hospitals
AI/ML disruption from hyperscalers (AWS HealthLake, Google Cloud Healthcare API, Microsoft Cloud for Healthcare) offering commoditized analytics at lower price points
Intense competition from well-capitalized EHR vendors (Epic with Cogito, Oracle with Cerner analytics) that can cross-subsidize analytics to protect core EMR business
Specialized competitors (Arcadia, Innovaccer, Philips Wellcentive) targeting similar hospital analytics market with differentiated approaches
Customer switching costs declining as data interoperability improves, reducing platform stickiness
Difficulty differentiating analytics capabilities as AI/ML tools become commoditized
Negative free cash flow and operating cash flow near breakeven create liquidity risk and potential need for dilutive capital raises
Current ratio of 1.88 provides modest cushion, but cash burn trajectory critical given market cap of only $100M
Debt/equity of 0.52 manageable but limits financial flexibility for unprofitable company
Significant negative ROE (-30%) and ROA (-51%) indicate capital destruction, raising going-concern questions if profitability path unclear
moderate - Healthcare IT spending is more defensive than discretionary tech, as hospitals require analytics infrastructure regardless of economic conditions. However, hospital financial health directly impacts IT budget availability. During recessions, hospitals face margin pressure from lower patient volumes and payer mix deterioration, potentially delaying analytics platform purchases or expansions. Conversely, cost reduction pressure during downturns can accelerate adoption of analytics tools that demonstrate ROI. The company's negative margins make it more vulnerable to funding constraints in risk-off environments.
Rising interest rates negatively impact Health Catalyst through multiple channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly severe given negative cash flow; (2) Increased financing costs for hospital customers reduce available IT budgets; (3) Potential need to raise capital at unfavorable terms given cash burn. The company's 0.52 debt/equity ratio suggests moderate existing debt burden. As a small-cap growth stock trading at 0.4x sales, the valuation is highly sensitive to risk-free rate changes affecting growth stock multiples.
Moderate credit exposure through customer concentration risk. Hospital systems facing financial distress may delay payments, reduce platform usage, or terminate contracts. The company's accounts receivable quality depends on hospital financial health, which correlates with credit market conditions. Tighter credit markets can stress hospital balance sheets (many carry significant debt), potentially impacting Health Catalyst's revenue visibility. However, the SaaS model with upfront annual payments partially mitigates this risk.
Speculative growth/turnaround investors willing to accept high risk for potential multi-bagger returns if company achieves profitability. The 68% one-year decline and 0.4x P/S valuation suggest deep value/distressed opportunity, but negative margins and cash burn deter traditional value investors. Momentum investors have clearly exited. Current holders likely include contrarian funds betting on M&A, restructuring success, or healthcare IT sector recovery. High volatility and small market cap limit institutional ownership.
high - Small-cap unprofitable SaaS company with significant execution risk exhibits elevated volatility. The 20% three-month decline and 42% six-month decline demonstrate sharp drawdown risk. Low float and limited liquidity amplify price swings on company-specific news or sector rotation. Beta likely exceeds 1.5 relative to broader market given growth stock characteristics and financial distress signals.
